An investigational higher dose of spinal muscular atrophy drug nusinersen gains attention as the FDA and European Medicines ...

In a good-news-bad-news week for Biogen, the company will cut an undisclosed number of employees, just as a higher dose of ...

Access to the new Alzheimer's drugs is limited by strict eligibility criteria, long wait times, and a lack of infusion ...

Musk’s startup company Neuralink has tapped the University of Miami’s Miller School of Medicine to be the second site in the ...

Regulatory officials have identified 82 cases worldwide from the FDA Adverse Event Reporting System of anaphylaxis associated ...

ONWARD ARC-EX System for spinal cord injury is now available for purchase through VA Federal Supply Schedule and GSA Advantage platforms Partnership with Lovell Government Services is providing commer ...

The health activists argue that the government is empowered with effective law and policy tools and therefore should ...

Biogen’s applications for the higher dose regimen of spinal muscular atrophy (SMA) drug Spinraza are now under review in the US and Europe.

Elon Musk’s Neuralink has selected Miami as a clinical trial site for its brain-computer interface, the second U.S. site to ...

Biogen said the U.S. Food and Drug Administration has accepted its supplemental new-drug application, while the European Medicines Agency has validated its application, which confirms that the ...

Biogen BIIB announced that the FDA and EMA have accepted its regulatory filings seeking label expansion for a higher dose of ...

Patients’ rights advocates on Friday accused the Centre of reneging on its constitutional obligation to protect life and health after it told a court that patients with rare disorders such as spinal ...